Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy
- Results Presented at Society of Nuclear Medicine Annual Meeting - WASHINGTON, June 05, 2007 /PRNewswire-FirstCall/ -- Immunomedics, Inc. , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that initial results from...Immunomedics' hPAM4 Labeled With Yttrium-90 Receives Orphan Medicinal ...
MORRIS PLAINS, N.J., Dec. 19, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. ... About hPAM4. hPAM4 is a humanized monoclonal antibody targeting an epitope in the MUC1 ...Immunomedics' hPAM4 Labeled With Yttrium-90 Receives Fast Track ...
Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced ...Safety Study to Determine the Appropriate Dose of Antibody Against ...
Monitor the development of antibody formation to the hPAM4, when feasible. Targeting with 111In-hPAM4 will be compared to other radiological (e.g., CT) and ...Immunomedics Awarded U.S. Patent For Humanized PAM4 Monoclonal Antibody ...
hPAM4 is an important product candidate in our clinical pipeline. ... About hPAM4. hPAM4 is a humanized monoclonal antibody targeting an epitope in the MUC1 ...Immunomedics, Inc.' hPAM4 Labeled With Yttrium-90 Receives Fast Track ...
( IMMU)' hPAM4 Labeled With Yttrium-90 Receives Fast Track Designation From FDA ... (FDA) granting yttrium-90-labeled hPAM4 Fast Track designation for the treatment ...